Exelixis
Trade Exelixis 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About EXEL
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.
EXEL Key Statistics
Stock Snapshot
The current Exelixis(EXEL) stock price is $44.13, with a market capitalization of 11.81B. The stock trades at a price-to-earnings (P/E) ratio of 18.54.
During the trading session on 2026-01-11, Exelixis(EXEL) shares reached a daily high of $45.42 and a low of $43.88. At a current price of $44.13, the stock is +0.6% higher than the low and still -2.8% under the high.
Trading activity shows a volume of 2.83M, compared to an average daily volume of 2.28M.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.
Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.
EXEL News
Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnersh...
Wondering if Exelixis at a last close of US$46.19 still offers value, or if the easy money has already been made? This article walks through what the numbers ar...
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $52 from $49 and keeps a Buy rating on the shares after the company an...
Analyst ratings
50%
of 22 ratingsMore EXEL News
Exelixis recently announced that President and CEO Michael M. Morrissey, Ph.D., had provided a corporate overview at the J.P. Morgan 2026 Healthcare Conference,...
BofA downgraded Exelixis (EXEL) to Underperform from Neutral with a price target of $41, down from $43, citing valuation and limited high-impact catalysts seen...